Reply - 06/09/18
Doi : 10.1016/j.jaci.2018.06.021
Silvia Bulfone-Paus, MD, PhD a 
, Rajia Bahri, PhD a, Mohamed H. Shamji, PhD b, Adnan Custovic, MD, PhD c, Paul J. Turner, FRACP, PhD c
, Rajia Bahri, PhD a, Mohamed H. Shamji, PhD b, Adnan Custovic, MD, PhD c, Paul J. Turner, FRACP, PhD c a Division of Musculoskeletal and Dermatological Sciences & Manchester Collaborative Centre for Inflammation Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom
b Section of Allergy and Clinical Immunology, National Heart and Lung Institute and MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, London, United Kingdom
c Section of Paediatrics (Allergy and Infectious Diseases) and MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, London, United Kingdom
Le texte complet de cet article est disponible en PDF.
| This study was supported by the following grants: Medical Research Council (MRC) Confidence-in-Concepts award to the University of Manchester (subaward to S.B.-P. and P.J.T., reference MC-PC-15038); an MRC Clinician Scientist award (reference MR/K010468/1 to P.J.T.). P.J.T. and A.C. are supported by the Imperial/National Institute for Health Research (NIHR) Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health. |
|
| Disclosure of potential conflict of interest: S. Bulfone-Paus has received grants from the UK Medical Research Council, GlaxoSmithKline, and Novartis and has received personal fees from EUROIMMUN AG. M. H. Shamji has received grants from ALK-Abelló, Regeneron, Merck, ASIT Biotech.sa, and the Immune Tolerance Network and has received personal fees from ASIT Biotech.sa, ALK-Abelló, Allergopharma, and UCB. A. Custovic has received personal fees from Novartis, Regeneron/Sano fi, ALK-Abelló, Bayer, Thermo Fisher, GlaxoSmithKline, and Boehringer Ingelheim. P. J. Turner has received grants from the UK Medical Research Council, the National Institute for Health Research, and the European Commission FP7 scheme, and personal fees from Aimmune Therapeutics. R. Bahri declares no relevant conflicts of interests. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 142 - N° 3
P. 1019 - septembre 2018 Retour au numéro
Article précédent
- Mast cell activation test versus basophil activation test and related competing issues
- Salvaore Chirumbolo, Geir Bjørklund, Antonio Vella
- Information for Readers
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?